These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
274 related articles for article (PubMed ID: 29232473)
1. Front-line therapy of advanced epithelial ovarian cancer: standard treatment. Marth C; Reimer D; Zeimet AG Ann Oncol; 2017 Nov; 28(suppl_8):viii36-viii39. PubMed ID: 29232473 [TBL] [Abstract][Full Text] [Related]
2. First-line and maintenance therapy for ovarian cancer: current status and future directions. González-Martín A; Sánchez-Lorenzo L; Bratos R; Márquez R; Chiva L Drugs; 2014 Jun; 74(8):879-89. PubMed ID: 24848752 [TBL] [Abstract][Full Text] [Related]
3. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Dhillon S BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884 [TBL] [Abstract][Full Text] [Related]
4. Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer? Monk BJ; Chan JK Ann Oncol; 2017 Nov; 28(suppl_8):viii40-viii45. PubMed ID: 29232474 [TBL] [Abstract][Full Text] [Related]
5. Impact of bevacizumab containing first line chemotherapy on recurrent disease in epithelial ovarian cancer: A case-control study. Petrillo M; Amadio G; Salutari V; Paris I; Di Stefano MG; Ferandina G; Scambia G; Fagotti A Gynecol Oncol; 2016 Aug; 142(2):231-6. PubMed ID: 27215633 [TBL] [Abstract][Full Text] [Related]
6. Incorporation of bevacizumab in the primary treatment of ovarian cancer. Burger RA; Brady MF; Bookman MA; Fleming GF; Monk BJ; Huang H; Mannel RS; Homesley HD; Fowler J; Greer BE; Boente M; Birrer MJ; Liang SX; N Engl J Med; 2011 Dec; 365(26):2473-83. PubMed ID: 22204724 [TBL] [Abstract][Full Text] [Related]
8. Bevacizumab with dose-dense paclitaxel/carboplatin as first-line chemotherapy for advanced ovarian cancer. Zhang L; Zhou Q Eur J Pharmacol; 2018 Oct; 837():64-71. PubMed ID: 30059681 [TBL] [Abstract][Full Text] [Related]
9. Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. Hall M; Bertelli G; Li L; Green C; Chan S; Yeoh CC; Hasan J; Jones R; Ograbek A; Perren TJ Int J Gynecol Cancer; 2020 Feb; 30(2):213-220. PubMed ID: 31780570 [TBL] [Abstract][Full Text] [Related]
10. Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen? Lee MX; Tan DS J Gynecol Oncol; 2018 Nov; 29(6):e96. PubMed ID: 30207104 [TBL] [Abstract][Full Text] [Related]
11. Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer. Markman M Gynecol Oncol; 2013 Oct; 131(1):241-5. PubMed ID: 23726888 [TBL] [Abstract][Full Text] [Related]
12. Impact of Adding Bevacizumab to Paclitaxel + Carboplatin for Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Propensity Score Matching Analysis. Hirasawa T; Machida H; Iida T; Ikeda M; Shida M; Mikami M Tokai J Exp Clin Med; 2018 Sep; 43(3):85-89. PubMed ID: 30191541 [TBL] [Abstract][Full Text] [Related]
13. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14). Cognetti F; Bagnato A; Colombo N; Savarese A; Scambia G; Sehouli J; Wimberger P; Sorio R; Harter P; Mari E; McIntosh S; Nathan F; Pemberton K; Baumann K Gynecol Oncol; 2013 Jul; 130(1):31-7. PubMed ID: 23234805 [TBL] [Abstract][Full Text] [Related]
14. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. Hainsworth JD; Thompson DS; Bismayer JA; Gian VG; Merritt WM; Whorf RC; Finney LH; Dudley BS Cancer Med; 2015 May; 4(5):673-81. PubMed ID: 25556916 [TBL] [Abstract][Full Text] [Related]
15. A systematic overview of chemotherapy effects in ovarian cancer. Högberg T; Glimelius B; Nygren P; Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940 [TBL] [Abstract][Full Text] [Related]
16. Dose-dense therapy is of benefit in primary treatment of ovarian cancer? In favor. Katsumata N Ann Oncol; 2011 Dec; 22 Suppl 8():viii29-viii32. PubMed ID: 22180396 [TBL] [Abstract][Full Text] [Related]
17. Dose-dense approaches to ovarian cancer treatment. Katsumata N Curr Treat Options Oncol; 2015 May; 16(5):21. PubMed ID: 25859831 [TBL] [Abstract][Full Text] [Related]
18. A phase 3 trial of bevacizumab in ovarian cancer. Perren TJ; Swart AM; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Kurzeder C; du Bois A; Sehouli J; Kimmig R; Stähle A; Collinson F; Essapen S; Gourley C; Lortholary A; Selle F; Mirza MR; Leminen A; Plante M; Stark D; Qian W; Parmar MK; Oza AM; N Engl J Med; 2011 Dec; 365(26):2484-96. PubMed ID: 22204725 [TBL] [Abstract][Full Text] [Related]
19. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Katsumata N; Yasuda M; Isonishi S; Takahashi F; Michimae H; Kimura E; Aoki D; Jobo T; Kodama S; Terauchi F; Sugiyama T; Ochiai K; Lancet Oncol; 2013 Sep; 14(10):1020-6. PubMed ID: 23948349 [TBL] [Abstract][Full Text] [Related]
20. Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer. Singapore Cancer Network (SCAN) Gynaecological Cancers Systemic Therapy Workgroup Ann Acad Med Singap; 2015 Oct; 44(10):421-33. PubMed ID: 26763060 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]